Scientists discover disturbing 'unexpected' side effect of new mRNA jab

Patients given experimental mRNA jabs for HIV have developed an 'unexpected' side-effect needing further investigation, experts say.
About 7 per cent of volunteers given the jabs in the trial broke out in an itchy bumpy rash called hives.
While this rash disappeared for some sufferers, over half were still experiencing bouts a year after injection.
Some were still breaking out in hives almost three years after receiving the jab.
Experts analysing the data noted volunteers who suffered the hive reaction were more likely to have received the Moderna mRNA Covid vaccine in the past.
However, they added this finding didn't necessarily mean the two are linked and how and why the new jabs were provoking this reaction remained unclear.
The reaction was seen across a trio of potential HIV jabs manufactured by Moderna with the same mRNA technology famously used in Covid vaccines.
These jabs were tested on a group of 108 HIV-negative volunteers to measure their overall safety.
Volunteers were split into three groups, each receiving one of the three different vaccine formulas.
These groups were then split further into a high-dose or low-dose cohort for a total of six different cohorts.
After the initial injection repeat doses were administered at 12 weeks and then again at 24 weeks.
In their report experts from the University of Pittsburgh found the jabs to be 'generally safe and tolerable'.
However, they noted the hive reaction in seven participants — seen across all three vaccine formulas— was an 'unexpected' result.
Writing in the Annals of Internal Medicine, they said what was causing the hives in some people was unclear.
But they theorised it could be due to a combination of vaccine components, the dosage, and an unknown environmental factor.
The scientists said while mRNA vaccine technology continued to hold great promise, further research was needed into what was causing this hive reaction.
Independent experts, writing in a linked editorial, agreed.
They said that while hives is, overall, a minor ailment it can still contribute to vaccine hesitancy and hinder vaccine uptake.
The experts said more work was needed to understand the mechanisms behind the reaction 'to ultimately promote the safety and uptake of vaccines'.
There is currently no cure for HIV, which affects approximately 100,000 Britons and 1.2million Americans. Although there are prevention drugs, they need to be taken daily.
WHAT IS HIV?
HIV (human immunodeficiency virus) is a virus that damages the cells in your immune system and weakens your ability to fight everyday infections and disease.
AIDS (acquired immune deficiency syndrome) is the name used to describe a number of potentially life-threatening infections and illnesses that happen when your immune system has been severely damaged by the HIV virus.
While AIDS cannot be transmitted from 1 person to another, the HIV virus can.
There's currently no cure for HIV, but there are very effective drug treatments that enable most people with the virus to live a long and healthy life.
With an early diagnosis and effective treatments, most people with HIV will not develop any AIDS-related illnesses and will live a near-normal lifespan.
Source: NHS
A vaccine that offers lifetime protection from the virus would be a breakthrough for the disease that has claimed millions of lives.
But despite 40 years of research since HIV was first identified, a vaccine has been elusive, with half-a-dozen real-world trials repeatedly failing to deliver on initial results.
HIV is a virus that damages the cells in your immune system and weakens your ability to fight everyday infections and disease.
AIDS is the name used to describe the potentially life-threatening infections and illnesses that happen when your immune system has been severely damaged by HIV.
While AIDS cannot be transmitted from one person to another, the HIV virus can.
There's currently no cure for HIV, but there are extremely effective treatments.
With an early diagnosis most people with HIV will not develop any AIDS-related illnesses and will live a near-normal lifespan.
Currently health officials focus on measures like encouraging safe sex and providing patients medications that stop HIV from spreading.
HIV is estimated to have claimed over 40million lives since it first emerged.
While new HIV diagnoses in the UK had been trending down for years, there has been a recent surge of new cases.
In 2023, there were just over 6,400 HIV diagnoses in the UK, a 46 per cent increase compared to the year before.
Health officials have said the wave of new cases could be a sign of ongoing transmission or a reflection of migration bringing more people with HIV into the country.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

BBC News

a day ago

• BBC News

'I took photos of my mum's dementia decline to show our long goodbye'

A woman who recorded her mother's decline with dementia in hundreds of photos said it was "hard" to capture the moments when she began not to recognise her own Harris started taking the shots of 87-year-old Vivian Harris while she was in a care home when the Covid pandemic struck in later, she has put the images together to show people the "raw end" of dementia in an exhibition called Our Long Goodbye, which has now opened in Sale, Greater Manchester-based artist said: "It's like you're saying goodbye somebody while they're still alive". "Mum moved into a care home, and then Covid happened, and I suddenly couldn't be with her," said Ms Harris, 60.A year later she noticed her mum was was struggling with her memory. She started to take shots of her mum through windows at the care home, and then continued when lockdown lifted, taking more than 1,500 photographs."Without realising it, I had created a visual archive of our relationship with dementia and each other," she said. Each click of her camera captured the personal challenges of dementia, but also moments of love, joy and said: "A lot of it is about my mum sleeping and not recognising us, and it's hard, but I think people need to see that because of a lot of it is behind closed doors"I think let's talk about that rather than forget it's there or tuck it away."Her exhibition will also be on show in Huddersfield and Stockport before finishing in Manchester at the end of the year."There are lots of things I've chosen not to show in this exhibition which are probably the more slightly brutal end of things, just because I'm not sure what my mum would have thought about that," she said. 'Talk about it' Ms Harris has described the exhibition as focused on the idea of "anticipatory grief" and "mourning the loss of someone before they actually die".Dementia is defined by the NHS as a syndrome associated with an ongoing decline in the functioning of the brain, with many different types, including Alzheimer' include memory loss, trouble speaking and understanding, changes in mood and the way you speak, think, feel and 2014, Ms Harris she has been the lead artist with Storybox, a creative project for dementia parents and their Harris said: "I'm hoping it will help other people maybe write about it and talk about it, and other people who don't know much about dementia to start conversations about it."Each exhibition venue will have one free writing workshop with the first taking place on Saturday afternoon at Waterside in Sale."Our Long Goodbye is just one story, there are so many more about dementia and Alzheimer's," said Ms Harris. Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.

Wales Online

a day ago

• Wales Online

The new weight loss pill showing significant results within 12 weeks

The new weight loss pill showing significant results within 12 weeks The weight loss pill has showed promise in new trials with some reporting up to 24% weight loss The experimental drug tests have shown up to 24% weight loss (Image: PA ) An early study has found that a new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight. It has found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. ‌ Weight loss jabs have been hailed as transformative by NHS leaders. ‌ But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Stay informed on the latest health news by signing up to our newsletter here Article continues below Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body - GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. ‌ Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. "These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity," the authors wrote. "Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment." ‌ The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. ‌ The authors wrote: "Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. "Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen." The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Article continues below Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

South Wales Guardian

2 days ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.